Persistent Corneal Epithelial Defects Therapeutics Market Size Anticipated to Boost at a CAGR of 18.69% for the Study Period 2018-2030 | DelveInsight

The Persistent Corneal Epithelial Defects pipeline therapies expected to get launched in the forecasted period include Nexagon, ST266, RGN-259, REC-0559, and others. These are expected to create a positive shift in the Persistent Corneal Epithelial Defects market during the forecast period (2021-2030).

LAS VEGAS, Oct. 12, 2021 /PRNewswire/ -- DelveInsight's Persistent Corneal Epithelial Defects (PEDs or PCEDs) Market report offers detailed information on current treatment practices, emerging drugs, Persistent Corneal Epithelial Defects market share of the individual therapies, current and forecasted Persistent Corneal Epithelial Defects market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

Some of the key takeaways from the Persistent Corneal Epithelial Defects Market Report:

• As per DelveInsight's estimate, the total Persistent Corneal Epithelial Defects incident cases in 2020 were reported to be 241,452 in the 7MM.
• DelveInsight estimates that PCED affects males more as compared to females. 
• The PCED therapy market space is monopolized by aggressive lubrication, punctal occlusion, bandage soft contact lens, pressure patching, tetracyclines, prophylactic topical antibiotics, and steroids. 
• The Persistent Corneal Epithelial Defects therapeutic market size appears to be dominated by the United States in 2020, worth USD 83.9 million. 
• Key pharmaceutical and biotech companies actively engaged in the Persistent Corneal Epithelial Defects market space include OcuNexus Therapeutics, Eyevance Pharmaceuticals, and Noveome Biotherapeutics, among others.
• The Persistent Corneal Epithelial Defects pipeline therapies expected to launch in the forecasted period (2021-2030) include Nexagon, ST266, RGN-259, REC-0559, and others. The anticipated launch of the pipeline therapies is expected to create a positive shift in the market during the forecast period (2021-2030).
• Nexagon (OcuNexus Therapeutics, Eyevance Pharmaceuticals) is a first-in-class natural, antisense therapy that downregulates the cell membrane hemichannel forming protein, connexin43 (Cx43).
• The demand for novel therapies with the absence of key players led to the boosted R&D from the academic-industry partnership that led to the prompting of open innovation and prioritizing the targeting of PED. Novel therapies being investigated recently are beginning to show promise in the treatment of the nonhealing corneal epithelium.

Download Persistent Corneal Epithelial Defects Market Snapshot report to understand which Persistent Corneal Epithelial Defects drug is going to capture the maximum market share @ Persistent Corneal Epithelial Defects Therapy Market Analysis and Forecast 

Persistent Corneal Epithelial Defects: Disease Overview

Persistent Corneal Epithelial Defects (PCED/ PED) are characterized by the failure of the rapid re-epithelialization and closure within 10-14 days after a corneal injury, even with standard supportive treatment. 

 Persistent Corneal Epithelial Defects Epidemiological Segmentation

DelveInsight's Persistent Corneal Epithelial Defects Market Insights Report offers historical as well as forecasted epidemiological analysis during the study period 2018-30 in the 7MM segmented into:

• Total  Persistent Corneal Epithelial Defects Incident Cases 
• Gender-specific PCED Incidence 
• Etiology-specific  Persistent Corneal Epithelial Defects Incidence 

Understand how Persistent Corneal Epithelial Defects Epidemiological Trends are going to shape by 2030 in 7 Major Markets by downloading @ Persistent Corneal Epithelial Defects Epidemiology Market Report Summary

Present PCED Therapeutics Market Outlook 

The current approaches include aggressive lubrication, punctal occlusion, bandage soft contact lens, pressure patching, tetracyclines, prophylactic topical antibiotics, and steroids. Membrane grafting, autologous serum, scleral contact lenses, and others are available for relapse cases. Persistent epithelial defects of the cornea can be challenging to even the experienced ophthalmologist. 

Although several therapies exist and an increasing number of novel approaches are emerging, treatment of PEDs can still be quite challenging. It is essential to treat the underlying causative condition, including infection, limbal stem cell deficiency, or diabetes, to facilitate wound healing. In individuals with PCEDs, there is a high risk of infection or further injury resulting in permanent vision loss due to corneal scarring, infection, neovascularization, and incomplete wound healing. The current PCED therapy market has several unmet needs in the form of a lack of adequate and curative therapies that can heal or reverse the damage to the cornea. 

PCED Market: Unmet Needs and Forecasted Scenario

Several pharmaceutical and biotech companies such as OcuNexus Therapeutics, Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, and several others are working to keep the market growth steady, showcasing an encouraging future picture. 

DelveInsight estimates that with an entry of pharmaceutical pharma players and the expected launch of novel therapies, the futuristic outlook of the PCED market is anticipated to be promising during the next decade. Besides, a better understanding of the condition of increased healthcare expenditure and funding from international organizations shall further add to the growth of the Persistent Corneal Epithelial Defects market share. 

Know which therapy is expected to score the touchdown first @ Persistent Corneal Epithelial Defects Therapeutic Pipeline and Market Forecast

Persistent Corneal Epithelial Defects Pipeline Therapies in focus in the report analysis

• Nexagon: OcuNexus Therapeutics
• ST266: Noveome Biotherapeutics
• RGN-259: RegeneRx Biopharmaceuticals
• REC-0559: Recordati Rare Diseases/Mimetech

Learn more about available treatments @ Persistent Corneal Epithelial Defects Drug Pipeline Therapies 

Persistent Corneal Epithelial Defects Market Dynamics

Persistent Corneal Epithelial Defects Market to grow due to rising prevalence and increased awareness about the PED and its association with other diseases and its detection. Identifying potential targets, orphan designations, market exclusivity, support from various organizations are attracting the companies to develop novel therapies, which may increase the future Persistent Corneal Epithelial Defects market growth.

Nevertheless, the growth of the Persistent Corneal Epithelial Defects Market may be hindered by the poor response rate and various side effects of the available treatment option. Also, stringent regulatory procedures by regulatory authorities on medication and devices are hampering the persistent epithelial defects treatments market.

Discover more about the future market share of the therapies @ Persistent Corneal Epithelial Defects Treatment Market Landscape and Forecast 

Scope of the Persistent Corneal Epithelial Defects Market Report 
Coverage: 7MM (the US, EU5, and Japan)
Study Period: 2018-30
Key Companies: OcuNexus Therapeutics, Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, and several others. 
Key Persistent Corneal Epithelial Defects Pipeline Therapies: Nexagon, ST266, RGN-259, REC-0559, and several others. 
Persistent Corneal Epithelial Defects Market Segmentation: By Geography, By Persistent Corneal Epithelial Defects Therapies
Analysis: Comparative and conjoint analysis of Persistent Corneal Epithelial Defects Emerging Therapies
Tools used: SWOT analysis, Conjoint Analysis, Porter's Five Forces, PESTLE analysis, BCG Matrix analysis methods.
Case Studies
KOL's Views
Analyst's Views

Drop by to learn more about the future market trends @ Persistent Corneal Epithelial Defects Market Landscape and Forecast 

Table of Contents 

Get in touch with our Business executive for Rich and Deep Market Assessment and Consulting Solutions 

Related Reports 

Severe Hypertriglyceridemia Market 
DelveInsight's "Severe Hypertriglyceridemia (SHTG) Market Insights, Epidemiology, and Market Forecast-2030" report.

Smoking Cessation And Nicotine Addiction Market 
DelveInsight's "Smoking Cessation and Nicotine Addiction Market Insights, Epidemiology, and Market Forecast-2030" report. 

Uveal Neoplasms Market 
DelveInsight's "Uveal Neoplasms Market Insights, Epidemiology, and Market Forecast-2030" report. 

Uveitis Market
DelveInsight's 'Uveitis-Market Insights, Epidemiology, and Market Forecast–2030' report. Key companies working in this domain are Sirion Therapeutics, Novartis, Valeant Pharmaceuticals International Inc, Aldeyra Therapeutics, Santen, EyeGate Pharmaceuticals, and others.

Varicose Veins Market 
DelveInsight's "Varicose Veins Market Insights, Epidemiology, and Market Forecast-2030" report. 

Suggested reading

Charcot-Marie-Tooth Disease Market 
Drones in Healthcare Delivery System 
Venous Thromboembolism Market Growth 
Duchenne Muscular Dystrophy Market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. Discover how DelveInsight helped a Europe-based large-cap pharma company assess its pipeline activities and make strategic decisions to outperform in the market through its Pharma and healthcare market competitive benchmarking services.

Contact Us
Shruti Thakur 
info@delveinsight.com  
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP